Women Health Expert GC-Rise Debuts at JPMorgan's Healthcare Conference in US

BEIJING, Jan. 12, 2012 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has debuted at J.P. Morgan's 30th annual Healthcare Conference in the United States.

Beijing-headquartered GC-Rise, which focuses on women's health in China, aims to take the opportunity to share its growth stories and seek collaborations with potential partners to help them tap China's big market.

The Healthcare conference, the industry's largest, is held from January 9-12 in San Francisco, California, GC-Rise's founder & chief executive officer Wren Zhang presented the company's growth roadmap at a luncheon on January 10.

"We offer exclusive agreements with producers of medicine, helping them with distribution and building their presence in China. Most of our partners come from the developed world - Japan, the United States and Europe. We provide one-stop services for them, from policy interpretation, public affairs management to patient education, from local registration, clinical trials, pricing to market promotion and brand-building," Zhang said.

China's female health care market is expected to grow at an annual compound rate of 20% between 2010 and 2015. Some segments, like anti-aging and reproductive health, will see growth as high as 35%, with the market expected to hit 247 billion RMB, Zhang cited data from the Ministry of Health.

GC-Rise, invited as one of the emerging fast-growth companies by J.P. Morgan, saw its operating revenues rising more than 270% on average per annum from 2008 to 2010, and was recently listed as one of the Deloitte & Touche's 50 top-performing Chinese high-tech companies.

The company is solidly positioned in five rapidly growing segments: anti-aging products, reproductive health products, tumor products, dermatological and beauty products, and mental health treatments.

"We are confident of strong demand in the 2010-2015 period, giving us annual compound growth of 61%," said Zhang.

The healthcare investment symposium brings together more than 300 companies, both public and private, and the companies, including global industry leaders, emerging fast-growth companies, innovative technology creators have delivered presentations to more than 4,000 investors.

About GC-Rise Pharmaceutical Co. Ltd

GC-Rise Pharmaceutical Co. Ltd, established in 2008, is a wholly-owned foreign enterprise invested by INVENTAGES, a major European healthcare and biotechnology venture capital investor, focuses on women's health. Taking "Devoted to human healthcare and a better life" as our mission, the company makes full use of the business networks of our strategic partners in the United States, Europe and Japan, their rich experiences in clinical development, clinical trials and registration in China and their strong strength in distributions, hospital sales and marketing, so as to provide safe, novel and highly efficient medical products and treatment ideas for Chinese women patients.

Please log on http://www.gc-rise.com/ to know more information.

SOURCE GC-Rise Pharmaceutical Co. Ltd

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.